{
    "clinical_study": {
        "@rank": "82499", 
        "acronym": "OTT 14-01", 
        "arm_group": {
            "arm_group_label": "Feasibility study", 
            "arm_group_type": "Other", 
            "description": "All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this project is to assess the feasibility of collecting plasma samples for\n      cardiac biomarker assessment, and to identify if there is an associations between the\n      biomarkers, echocardiographic features and the cardiac PET scan results (in patients\n      receiving radiation therapy). This is the first step in a research program that has an\n      overall goal of being able to predict early-treatment induced cardiotoxicity in patients\n      with breast cancer."
        }, 
        "brief_title": "A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Ductal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Stage I-III, HER2-neu positive invasive ductal carcinoma\n\n          2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin,\n             Cyclophosphamide and Docetaxel (FEC-D) chemotherapy\n\n          3. Scheduled to receive adjuvant Trastuzumab\n\n          4. ECOG Performance status 0-2\n\n          5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac\n             ejection fraction of \u2265 55%.  Additionally, breast cancer patients\u226545 years of age and\n             scheduled to receive whole breast radiation therapy will receive two cardiac PET\n             scans.\n\n        Exclusion Criteria:\n\n          1. Prior anthracycline chemotherapy\n\n          2. History of dilated cardiomyopathy, congestive heart failure, or coronary artery\n             disease\n\n          3. Life expectancy less than 15 months\n\n          4. Pregnant or lactating women\n\n          5. Use of beta receptor antagonists, calcium channel antagonists, angiotensin converting\n             enzyme inhibitors, or angiotensin receptor inhibitors at baseline.\n\n          6. Previous chest wall/breast or nodal radiation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156648", 
            "org_study_id": "20140259-01H"
        }, 
        "intervention": {
            "arm_group_label": "Feasibility study", 
            "description": "All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.", 
            "intervention_name": "Feasibility study", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Invasive ductal", 
            "HER2-neu positive"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ottawa", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "K1H 8L6"
                }, 
                "name": "The Ottawa Hospital Cancer Centre"
            }, 
            "investigator": {
                "last_name": "Jeffrey Sulpher, Fellow", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Feasibility Study for Women Receiving Adjuvant or Neo-adjuvant Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma", 
        "overall_contact": {
            "email": "sdent@toh.on.ca", 
            "last_name": "Susan Dent, Oncologist", 
            "phone": "613-737-7700", 
            "phone_ext": "70170"
        }, 
        "overall_official": {
            "affiliation": "The Ottawa Hospital Cancer Centre", 
            "last_name": "Susan Dent, Oncologist", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Recruitment rates", 
            "safety_issue": "No", 
            "time_frame": "every 4 weeks up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156648"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To measure biomarkers, myocardial perfusion, cardiac adverse events and peak systolic longitudinal strain.", 
            "measure": "Cardiotoxicity", 
            "safety_issue": "No", 
            "time_frame": "Once when the last participant completes week 57"
        }, 
        "source": "Ottawa Hospital Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ottawa Hospital Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}